ANDREA SANCHEZ NAVARRO

Dr. ANDREA SANCHEZ NAVARRO

University of Pennsylvania Perelman School of Medicine
+1

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
ANDREA SANCHEZ NAVARROANDREA SANCHEZ NAVARRO
ANDREA SANCHEZ NAVARRO
IGIsaac González-Soria
Isaac González-Soria
RCRebecca Caldiño-Bohn
Rebecca Caldiño-Bohn
NBNorma A. Bobadilla
Norma A. Bobadilla
Serpins are a superfamily of proteins characterized by their common function as serine protease inhibitors. So far, 36 serpins from nine clades have been identified. These proteins are expressed in all the organs and are involved in multiple important functions such as the regulation of blood pressure, hormone transport, insulin sensitivity, and the inflammatory response. Diseases such as obesity, diabetes, cardiovascular, and kidney disorders are intensively studied to find effective therapeutic targets. Given serpins' outstanding functionality, the deficiency or overexpression of certain types of serpin have been associated with diverse pathophysiological events. In particular, we will focus on reviewing the studies evaluating the participation of serpins, and particularly SerpinA3, in diverse diseases that occur in relevant organs such as the brain, retinas, corneas, lungs, cardiac vasculature, and kidneys. In this review, we summarize the role of serpins in physiological and pathophysiological processes, as well as recent evidence on the crucial role of SerpinA3 in several pathologies. Finally, we emphasize the importance of SerpinA3 in regulating cellular processes such as angiogenesis, apoptosis, fibrosis, oxidative stress, and the inflammatory response.

25 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ILIxchel Lima-Posada
Ixchel Lima-Posada
CPCinthya Portas-Cortés
Cinthya Portas-Cortés
RPRosalba Pérez-Villalva
Rosalba Pérez-Villalva
FFFrancesco Fontana
Francesco Fontana
RRRoxana Rodríguez-Romo
Roxana Rodríguez-Romo
Norma A BobadillaNorma A Bobadilla
Norma A Bobadilla
This study evaluated if there is a sexual dimorphism in the acute kidney injury (AKI) to chronic kidney disease (CKD) transition and the time-course of the potential mechanisms involved in the dimorphic response. Female and male rats were divided into sham-operated or underwent 45-min renal ischemia (F + IR, and M + IR). All groups were studied at 24-h and 1, 2, 3, or 4-months post-ischemia. Additionally, oophorectomized rats were divided into sham or IR groups. After 24-h, AKI extent was simllar in females and males, but female rats exhibited less oxidative stress and increased renal GSH content. After 4-months and despite similar AKI, the M + IR group developed CKD characterized by proteinuria, tubulointerstitial fibrosis, glomerular hypertrophy, increased oxidative stress and a reduction in HIF1α and VEGF from the 1st-month and persisting throughout the time-course studied. Interestingly, the F + IR group did not develop CKD due to lesser oxidative stress and increased eNOS, TGFβ and HIF1α mRNA levels from the 1st-month after IR. Whereas, oophorectomized rats did develop CKD. We found a sexual dimorphic response in the AKI to CKD transition. Early antioxidant defense and higher TGFβ, HIF1α and eNOS were among the renoprotective mechanisms that the F + IR group demonstrated.

17 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANDREA SANCHEZ NAVARROANDREA SANCHEZ NAVARRO
ANDREA SANCHEZ NAVARRO
JMJuan M. Mejía-Vilet
Juan M. Mejía-Vilet
RPRosalba Pérez-Villalva
Rosalba Pérez-Villalva
DCDiego L. Carrillo-Pérez
Diego L. Carrillo-Pérez
BMBrenda Marquina-Castillo
Brenda Marquina-Castillo
Norma A BobadillaNorma A Bobadilla
Norma A Bobadilla
Recognizing patients at early phases of chronic kidney disease (CKD) is difficult, and it is even more challenging to predict acute kidney injury (AKI) and its transition to CKD. The gold standard to timely identify renal fibrosis is the kidney biopsy, an invasive procedure not usually performed for this purpose in clinical practice. SerpinA3 was identified by high-resolution-mass-spectrometry in urines from animals with CKD. An early and progressive elevation of urinary SerpinA3 (uSerpinA3) was observed during the AKI to CKD transition together with SerpinA3 relocation from the cytoplasm to the apical tubular membrane in the rat kidney. uSerpinA3/alpha-1-antichymotrypsin was significantly increased in patients with CKD secondary to focal and segmental glomerulosclerosis (FSGS), ANCA associated vasculitis (AAV) and proliferative class III and IV lupus nephritis (LN). uSerpinA3 levels were independently and positively associated with renal fibrosis. In patients with class V LN, uSerpinA3 levels were not different from healthy volunteers. uSerpinA3 was not found in patients with systemic inflammatory diseases without renal dysfunction. Our observations suggest that uSerpinA3 can detect renal fibrosis and inflammation, with a particular potential for the early detection of AKI to CKD transition and for the differentiation among lupus nephritis classes III/IV and V.

1 January 2015 in International Journal of Biological Sciences
Verified
Journal Article
Open access
Jonatan Barrera-ChimalJonatan Barrera-Chimal
Jonatan Barrera-Chimal
RPRosalba Pérez-Villalva
Rosalba Pérez-Villalva
JOJuan Antonio Ortega
Juan Antonio Ortega
ANDREA SANCHEZ NAVARROANDREA SANCHEZ NAVARRO
ANDREA SANCHEZ NAVARRO
RRRoxana Rodríguez-Romo
Roxana Rodríguez-Romo
Norma A BobadillaNorma A Bobadilla
Norma A Bobadilla
Administration of the mineralocorticoid receptor antagonist spironolactone prevents the development of chronic kidney disease (CKD) after a severe ischemic injury. However, whether brief periods of ischemia lead to CKD and whether spironolactone administration after ischemia may be a useful therapeutic strategy to prevent the gradual deterioration of structure and function remains unexplored.

22 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ANDREA SANCHEZ NAVARROANDREA SANCHEZ NAVARRO
ANDREA SANCHEZ NAVARRO
RPRosalba Pérez-Villalva
Rosalba Pérez-Villalva
AMAdrián Rafael Murillo-De-Ozores
Adrián Rafael Murillo-De-Ozores
MMMiguel Ángel Martínez-Rojas
Miguel Ángel Martínez-Rojas
JRJesús Rafael Rodríguez‐Aguilera
Jesús Rafael Rodríguez‐Aguilera
Norma A BobadillaNorma A Bobadilla
Norma A Bobadilla
Chronic hypoxia is a major contributor to Chronic Kidney Disease (CKD) after Acute Kidney Injury (AKI). However, the temporal relation between the acute insult and maladaptive renal response to hypoxia remains unclear. In this study, we analyzed the time-course of renal hemodynamics, oxidative stress, inflammation, and fibrosis, as well as epigenetic modifications, with focus on HIF1α/VEGF signaling, in the AKI to CKD transition. Sham-operated, right nephrectomy (UNx), and UNx plus renal ischemia (IR + UNx) groups of rats were included and studied at 1, 2, 3, or 4 months. The IR + UNx group developed CKD characterized by progressive proteinuria, renal dysfunction, tubular proliferation, and fibrosis. At first month post-ischemia, there was a twofold significant increase in oxidative stress and reduction in global DNA methylation that was maintained throughout the study. Hif1α and Vegfa expression were depressed in the first and second-months post-ischemia, and then Hif1α but not Vegfa expression was recovered. Interestingly, hypermethylation of the Vegfa promoter gene at the HIF1α binding site was found, since early stages of the CKD progression. Our findings suggest that renal hypoperfusion, inefficient hypoxic response, increased oxidative stress, DNA hypomethylation, and, Vegfa promoter gene hypermethylation at HIF1α binding site, are early determinants of AKI-to-CKD transition.

1 June 2016 in Tissue Engineering Part A
Verified
Journal Article
Open access
OCOscar A. Carballo-Molina
Oscar A. Carballo-Molina
ANDREA SANCHEZ NAVARROANDREA SANCHEZ NAVARRO
ANDREA SANCHEZ NAVARRO
ALAdolfo López-Ornelas
Adolfo López-Ornelas
RLRolando Lara-Rodarte
Rolando Lara-Rodarte
PSPatricia Salazar
Patricia Salazar
IVIván Velasco
Iván Velasco
Cell therapy in experimental models of Parkinson's disease replaces the lost dopamine neurons (DAN), but we still need improved methods to guide dopaminergic axons (DAx) of grafted neurons to make proper connections. The protein Semaphorin 3C (Sema3C) attracts DAN axons and enhances their growth. In this work, we show that the hydrogel PuraMatrix, a self-assembling peptide-based matrix, incorporates Sema3C and releases it steadily during 4 weeks. We also tested if hydrogel-delivered Sema3C attracts DAx using a system of rat midbrain explants embedded in collagen gels. We show that Sema3C released by this hydrogel attracts DAx, in a similar way to pretectum, which is known to attract growing DAN axons. We assessed the effect of Sema3C on the growth of DAx using microfluidic devices. DAN from rat midbrain or those differentiated from human embryonic stem cells showed enhanced axonal extension when exposed to hydrogel-released Sema3C, similar to soluble Sema3C. Notably, DAN of human origin express the cognate Sema3C receptors, Neuropilin1 and Neuropilin2. These results show that PuraMatrix is able to incorporate and release Sema3C, and such delivery guides and promotes the axonal growth of DAN. This biocompatible hydrogel might be useful as a Sema3C carrier for in vivo studies in parkinsonian animal models.